news.cision.com

On January 27[th], the Department of Hand, Plastic, Reconstructive and Burn Surgery of the BG Trauma Center in Tübingen treated its first patients with the OPRA[™ ]Implant System, and became one of the first hospitals in Germany to utilize the technology in the treatment of thumb amputees. The department is an integral part of the BG Trauma Center and the Eberhard Karls University Tübingen. One of its main foci of treatment is the functional reconstruction of extremities. In the clinic, the specialists develop an individual treatment concept for each patient, and accompany them through

Zurich and Onto use AI to gain unbiased risk insight on its entire EV fleet

The Insurtech company Greater Than is deepening its collaboration with Zurich through an agreement with Onto, the UK's largest all-inclusive electric car subscription service. Through the collaboration, Onto and Zurich obtain predictive risk data, facilitating their joint mission to improve road safety and enable dynamic insurance solutions.Onto's entire EV fleet is now connected to Greater Than's Enerfy AI Risk Portfolio Tracker. At this first stage, the risk-insight will be used by Zurich and Onto to get a better understanding of the fleet’s risk – a springboard which enables the future

Basware’s Annual Report 2020 published

Basware Corporation, stock exchange release, February 23, 2021 at 11:00 am EETBasware Corporation’s Annual Report 2020 has been published. The Annual Report is attached to this release and available at the company website https://r.basware.com/annual-report-2020 The Annual Report includes Financial Statements for 2020, Auditor’s Report, Report of the Board of Directors, Corporate Governance Statement and Remuneration Report. Basware’s Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements for the first time. In line

Valmet has published the Annual Report and the Corporate Governance Statement for 2020

Tue, Feb 23, 2021 09:43 CET

Valmet has published the Annual Report and the Corporate Governance Statement for 2020 Valmet Oyj's stock exchange release on February 23, 2021 at 11:00 a.m. EET Valmet has today, on February 23, 2021, published its Annual Report for 2020 on the company's website at http://www.valmet.com/annualreport2020. The Annual Report consists of three separate parts: the Annual Review, the Financial Statements and the GRI Supplement. Besides the official Financial Statements, Valmet has for the first time published its financial statements also in European Single Electronic Format (ESEF). The

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 47 - 23 FEBRUARY 2021 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90/2020. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451

Hunter Group ASA - Memorandum of Agreement

Tue, Feb 23, 2021 09:34 CET

Oslo, 23 February 2021 Hunter Tankers AS, a wholly owned subsidiary of Hunter Group ASA, has signed a Memorandum of Agreement for the sale of it's oldest vessel, Hunter Atla (2019 blt), for USD 84.5m to a Eurasian buyer. The vessel is expected to be delivered to its new owner during March. Contact: Erik A.S. Frydendal, CEO, ef@huntergroup.no, Ph.: +47 957 72 947 Lars M. Brynildsrud, CFO, lb@huntergroup.no, Ph.: +47 932 60 882 This information is subject to disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

BioStock: Biologics are a success factor according to Lipum

Tue, Feb 23, 2021 09:30 CET

Lipum develops a new biological drug for chronic inflammatory diseases. According to one study, the probability for approval of biological drugs is almost twice as high as that of small molecules (new molecular entities, NME). This bodes well for Lipum’s drug candidate SOL-116, which is an antibody. In addition, it has the potential to achieve orphan drug status, which would further increase the chances as it provides many benefits during the development process.Read the full article at biostock.se:https://www.biostock.se/en/biologics-are-a-success-factor-according-to-lipum/ This is a

TietoEVRY concludes its share repurchase programme

Tue, Feb 23, 2021 09:30 CET

TietoEVRY Corporation Stock Exchange Release 23 February 2021 10.30 a.m. EET TietoEVRY has completed the share repurchase programme concerning the company’s own shares. The company announced the start of the programme on 17 February 2021. During a time period from 18 February to 22 February 2021, the company has acquired a total of 140 000 of its own shares in trading organized by Nasdaq Helsinki Ltd. The average purchase price per share was EUR 27.0787 and the total amount EUR 3 791 024.50. At the moment, the company holds a total of 150 978 own shares.

Keliber secures EUR 40 million investment from leading international mining company

Tue, Feb 23, 2021 09:17 CET

Keliber Oy and leading international mining company Sibanye-Stillwater Limited (www.sibanyestillwater.com) have entered into an investment agreement for an initial phased equity investment of EUR 30 million for approximately 30% shareholding in Keliber. In addition, existing shareholders will be offered to subscribe for shares for up to EUR 10 million on the same terms as the investment from Sibanye-Stillwater, securing Keliber bridge financing of in total EUR 40 million. Sibanye-Stillwater plans to play a key role as an industrial anchor investor in the project financing planned for mid-

Biohit Oyj Managers' Transactions

Tue, Feb 23, 2021 09:02 CET

23 February 2021 at 10.00 am local time (EET) Biohit Oyj: Managers' TransactionsPerson subject to the notification requirementName: Semi KorpelaPosition: Chief Executive OfficerIssuer: Biohit OyjLEI: 74370089ATTSNBXJVT29__________________________________________________Notification type: INITIAL NOTIFICATIONReference number: 74370089ATTSNBXJVT29_20210222152942_7Transaction date: 2021-02-19

Flagging notification in accordance with Chapter 9 Section 10 of the Finnish Securities Markets Act

Basware Corporation, stock exchange release, February 23, 2021 at 10.00 am EETBasware Corporation has received on February 22, 2021 the following notification pursuant to Chapter 9, Section 5 of the Finnish Securities Market Act from Long Path Partners LP according to which their total holding of shares of Basware Corporation has increased above ten (10) percent on February 22, 2021. According to the notification, the reason for the notification was an acquisition or disposal of shares or voting rights. Basware Corporation has one series of shares in which each share carries one vote.

The DEVOPS Conference builds groundswell and connects Agile and DevOps decision-makers

The need to deliver customer value faster is reflected in the favorite conference topics: Management & Culture, Agile transformation and Continuous Integration / Continuous Delivery.[The DEVOPS Conference logo banner] Helsinki, Finland, February 23 2021 -- Eficode, Europe's leading DevOps company, has combined its annual DEVOPS and CoDe-Conf events into a free online event: The DEVOPS Conference taking place on March 23 & 24, and keeps building a strong community of DevOps practitioners and information technology decision-makers. Through Eficode's research*,

Read original

iLOQ continues its successful cooperation with Kimi Räikkönen

Finnish digital locking innovator, iLOQ, has announced that it will continue its partnership with the former Formula 1 world champion, Kimi Räikkönen, also for the 2021 season. Driving again for the Alfa Romea Racing Orlen team, Kimi will put on his iLOQ-branded helmet after the winter break when pre-season testing begins in Bahrain in March.iLOQ has partnered with Kimi since 2019. Over the last two years, iLOQ has continued its significant growth path and has expanded its business into many new countries and markets. “Kimi’s time and commitment to iLOQ has been instrumental in

Partnership with Sibanye-Stillwater ensuring significant financing for Keliber’s lithium project

Keliber Oy (Keliber) and Sibanye Stillwater Limited (Sibanye-Stillwater) have signed an investment agreement on bridge financing of 40 million euros. This agreement enables Keliber to significantly advance its lithium project in Central Ostrobothnia, Finland. Keliber aims to start production in 2024. The demand for lithium is expected to surge as a result of increasing digitalization and electrification of transportation. Sibanye-Stillwater will subscribe for shares in Keliber for 15 million euros, and the current Keliber shareholders will subscribe for shares for up to 10 million euros.

Linxon wins substation order supporting German energy transition

Linxon will supply a 380-kilovolt (kV) Gas Insulated Switchgear (GIS) substation for the German transmission system operator TransnetBW in the town of Bühl, southwestern Germany.Upgrading and strengthening the ‘Badische Rheinschiene’ power link in the Rhine valley will give TransnetBW a stable grid to transmit electricity generated by northern windfarms to consumers in the south, while nuclear and coal power plants are being put out of service. It also supports stronger grid interconnections between Germany and other countries, such as France and Switzerland. “We are delighted to help

AddSecure Eco-Driving Challenge reduces 16 700 tons CO2

Tue, Feb 23, 2021 08:57 CET

During 2020, almost 11,000 drivers participated in the AddSecure Eco-Driving Challenge. The competition was a great success where about 72 companies, organized through 132 teams with approximately 7,200 vehicles, participated. The French transport company Ambroise won the most prestigious prize for making the largest reduction in CO2. AddSecure today announced the results from its competition within Eco-Driving 2020. The competition, called "AddSecure Eco-Driving Challenge", is voluntary among AddSecure’s Smart Transport customers and is based on the

Read original

Biostock: CombiGene is preparing for the clinic

CombiGene's year-end report for 2020, which was published last week, summarised what can be seen as a financially successful year with three new share issues and three series of warrants that brought in a total of SEK 89 million before issue costs. During the year, three research advances were also presented in preparation of the first study in humans with the gene therapy CG01 in epilepsy, which is planned to be initiated next year. CombiGene’s lipodystrophy project has also advanced and the company recently announced that they have received development funding from the EU Eurostars

Axactor SE - Acceptances received under mandatory offer

Tue, Feb 23, 2021 08:33 CET

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Reference is made to the mandatory offer dated 29 January 2021 (the "Mandatory Offer") to acquire all shares in Axactor SE (the "Company") at an offer price of NOK 8.00 per share, made by Geveran Trading Co. Limited, a company indirectly controlled by trusts established by Mr. John Fredriksen for the benefit of his immediate family ("Geveran"). On 22 February 2021,

Euronext Growth - Received application for admission to trading – Arctic Bioscience AS

Tue, Feb 23, 2021 08:31 CET

Oslo Børs has received an application for admission to trading on Euronext Growth from Arctic Bioscience AS.Oslo Børs has received an application for admission to trading on Euronext Growth from Arctic Bioscience AS. The Listing Committee has decided to admit the company to trading. It is stipulated that the company prior to the first day of trading must satisfy the admission requirements on Euronext Growth. The first trading date on Euronext Growth is expected to take place on 24 February 2021. Company information: Name: Arctic Bioscience AS Ticker: ABS ISIN: NO0010859580

ExpreS2ion and University of Bologna announce research collaboration to test HER2-cVLP in state-of-the-art breast cancer mice models

Hørsholm, Denmark, February 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") and the University of Bologna (“UniBo”) announce a research collaboration agreement (“Agreement”) which covers testing of the novel HER2-cVLP breast cancer vaccine program, including the selected lead candidate ES2B-C001, in proprietary state-of-the-art breast cancer mice models. The collaboration follows the recently presented in-licensing of the HER2-cVLP technology from AdaptVac. The outcome of the collaboration is expected to support ExpreS2ion’s breast cancer

Gjøa P1 starts production

Operator Neptune Energy and license partners Petoro, Wintershall Dea and OKEA today announce that production has started from the Gjøa P1 development in the Norwegian sector of the North Sea.Gjøa P1 is developed via a new subsea template tied back to the existing infrastructure at the Gjøa field. The P1 development enables the license to recover significant quantities of oil and gas from deeper reservoirs, as well as to utilize spare production capacity. The project is a two-well development with one oil and one gas producer. The gas well was successfully started up yesterday and thereby

Bioservo Technologies AB Year-End Report 2020

Net sales increase of 26% for the full year despite operating in a challenging business environment due to the COVID-19 pandemicFourth quarter in figures · Net sales SEK 2.0 M (2.4) · EBITDA of SEK -5.5 M (-5.5) · EBIT of SEK -8.1 M (-6.6) · Earnings for the period was SEK -8.1 M (-6.6) · Earnings per share before and after dilution amounted to SEK -0.55 (-0.52) Year End in figures · Net sales SEK 11.7 M (9.3) · EBITDA of SEK –20.6 M (-19.4) · EBIT of SEK -26.3 M (-23.2) · Earnings for the period was SEK -26.3 M (-23.2) · Earnings per share before and

Vision Direct enters high street thanks to new partnership with optician David Clulow